5 Predictions On OSI-906 Next Year

The median platelet http://www.selleckchem.com/products/AC-220.html count was 155 �� 109/L (range, 1-1547 �� 109/L). Cytogenetic analysis was successful in 1847 patients (72%) and classified according to IPSS score into good (normal, ?Y, del[5q], del[20q]), poor (chromosome 7 anomalies, complex [��3 abnormalities]), and intermediate (all other aberrations). Thus, the IPSS score could be calculated in 1847 patients. Seven hundred fifty-three patients were low risk, 704 were intermediate-1 risk, 293 were intermediate-2 risk, and 97 were high risk. Thrombocytopenia was present at diagnosis in 842 of 2565 patients with MDS (32.8%). Mild thrombocytopenia was observed in 473 patients (18.4%), 186 patients (7.3%) presented moderate thrombocytopenia, and 183 patients (7.1%) had severe thrombocytopenia. Patients with severe thrombocytopenia were more likely to have advanced IPSS stages (P http://www.selleck.cn/products/Romidepsin-FK228.html (LDH) levels ��340 U/L (P = .049) (Table 1). After adjustments for these variables, patients with WHO subtypes RAEB-1 or RAEB-2 had an adjusted 4.12-fold greater risk of severe thrombocytopenia compared with patients with other WHO subtypes. In addition, patients with intermediate-2 or high IPSS risk had an adjusted 1.99-fold greater risk of severe thrombocytopenia compared with patients with low or intermediate-1 risk. For survival analysis, patients were divided randomly into 2 equally sized subgroups: a Study Group (n = 1299 patients; training set) and a Test Group (n = 1266 patients; validation set). The characteristics of the Study and Test Groups are shown in Table 2. The median OS was 46 months in the Study and 38 months in the Test Group (P = .06) (Fig. 1, Top). In addition, the progression to acute leukemia at 2 years was 10% in the Study Group and 13% in the Test Group (P = .06) (Fig. 1, Bottom). These features confirmed the prognostic comparability of the 2 http://www.selleckchem.com/products/nutlin-3a.html groups. In the Study Group, after a median observation period of 18 months (range, 1-199 months), patients with severe thrombocytopenia at diagnosis had the shortest survival. The median OS in patients with platelet counts